Coverage
-
February 26, 2015
A New York federal judge on Thursday declined to review a suit against Eli Lilly & Co. over the labeling of its antidepressant Cymbalta that allegedly downplays its withdrawal symptoms, finding that the plaintiff had not introduced any new evidence that warranted a new look at the case.
3 other articles on this case.
View all »